Gibson Energy (OTCMKTS:GBNXF) versus Poxel (OTCMKTS:PXXLF) Head-To-Head Review

Gibson Energy (OTCMKTS:GBNXF) and Poxel (OTCMKTS:PXXLF) are both oils/energy companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Insider and Institutional Ownership

0.2% of Gibson Energy shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Gibson Energy and Poxel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gibson Energy	1.39%	22.50%	4.01%
Poxel	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings for Gibson Energy and Poxel, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gibson Energy	0	0	3	0	3.00
Poxel	0	0	0	0	N/A

Gibson Energy currently has a consensus target price of $25.25, suggesting a potential upside of 48.70%. Given Gibson Energy’s higher probable upside, research analysts clearly believe Gibson Energy is more favorable than Poxel.

Valuation & Earnings

This table compares Gibson Energy and Poxel’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gibson Energy	$8.16 billion	0.34	$158.69 million	$0.78	21.77
Poxel	$710,000.00	28.54	-$33.08 million	N/A	N/A

Gibson Energy has higher revenue and earnings than Poxel.

Volatility and Risk

Gibson Energy has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Poxel has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Summary

Gibson Energy beats Poxel on 9 of the 10 factors compared between the two stocks.

About Gibson Energy

Gibson Energy Inc., together with its subsidiaries, engages in the gathering, storage, optimization, processing, and marketing of liquids and refined products in Canada and the United States. It operates through Infrastructure and Marketing segments. The Infrastructure segment operates a network of liquid infrastructure assets that include oil terminals, rail loading and unloading facilities, gathering pipelines, a crude oil processing facility, and other terminals. The Marketing segment purchases, sells, stores, and optimizes hydrocarbon products, including crude oil, natural gas liquids, road asphalt, roofing flux, frac oils, light and heavy straight run distillates, vacuum gas oil, and an oil-based mud product. It serves producers, refiners, marketers, and integrated companies, as well as exploration and production companies. The company was formerly known as Gibson Energy Holdings ULC and changed its name to Gibson Energy Inc. in April 2011. Gibson Energy Inc. was founded in 1953 and is headquartered in Calgary, Canada.

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.